Does the media refer more to PCRX or NKTR?

In the previous week, Nektar Therapeutics had 2 more articles in the media than Pacira BioSciences. MarketBeat recorded 6 mentions for Nektar Therapeutics and 4 mentions for Pacira BioSciences. Nektar Therapeutics' average media sentiment score of 0.68 beat Pacira BioSciences' score of 0.62 indicating that Nektar Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pacira BioSciences 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nektar Therapeutics 0 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor PRGO or PCRX?

In the previous week, Perrigo had 4 more articles in the media than Pacira BioSciences. MarketBeat recorded 8 mentions for Perrigo and 4 mentions for Pacira BioSciences. Pacira BioSciences' average media sentiment score of 0.62 beat Perrigo's score of -0.47 indicating that Pacira BioSciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Perrigo 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 6 Negative mention(s) 0 Very Negative mention(s) Neutral Pacira BioSciences 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is OMER or PCRX more profitable?

Pacira BioSciences has a net margin of 0.70% compared to Omeros' net margin of 0.00%. Pacira BioSciences' return on equity of 10.24% beat Omeros' return on equity. Company Net Margins Return on Equity Return on Assets Omeros N/A -102.16% 64.87% Pacira BioSciences 0.70% 10.24% 5.47%

Does the media favor OMER or PCRX?

In the previous week, Pacira BioSciences had 1 more articles in the media than Omeros. MarketBeat recorded 4 mentions for Pacira BioSciences and 3 mentions for Omeros. Pacira BioSciences' average media sentiment score of 0.62 beat Omeros' score of 0.38 indicating that Pacira BioSciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Omeros 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Pacira BioSciences 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ASMB or PCRX?

In the previous week, Assembly Biosciences had 2 more articles in the media than Pacira BioSciences. MarketBeat recorded 6 mentions for Assembly Biosciences and 4 mentions for Pacira BioSciences. Pacira BioSciences' average media sentiment score of 0.62 beat Assembly Biosciences' score of 0.37 indicating that Pacira BioSciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Assembly Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Pacira BioSciences 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Pacira BioSciences (PCRX) Competitors

$23.21 +0.35 (+1.53%)

Closing price 04:00 PM Eastern

Extended Trading

$23.22 +0.01 (+0.04%)

As of 05:29 PM Eastern

Compare

PCRX vs. SUPN, NKTR, PRGO, OMER, and ASMB

Should you buy Pacira BioSciences stock or one of its competitors? MarketBeat compares Pacira BioSciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Pacira BioSciences include Supernus Pharmaceuticals (SUPN), Nektar Therapeutics (NKTR), Perrigo (PRGO), Omeros (OMER), and Assembly Biosciences (ASMB). These companies are all part of the "pharmaceuticals" industry.

How does Pacira BioSciences compare to Supernus Pharmaceuticals?

Pacira BioSciences (NASDAQ:PCRX) and Supernus Pharmaceuticals (NASDAQ:SUPN) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, media sentiment, dividends and valuation.

Pacira BioSciences has higher revenue and earnings than Supernus Pharmaceuticals. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pacira BioSciences	$726.41M	1.26	$7.03M	$0.12	193.42
Supernus Pharmaceuticals	$718.95M	3.69	-$38.55M	-$0.51	N/A

Pacira BioSciences currently has a consensus target price of $29.40, indicating a potential upside of 26.67%. Supernus Pharmaceuticals has a consensus target price of $62.17, indicating a potential upside of 36.15%. Given Supernus Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Supernus Pharmaceuticals is more favorable than Pacira BioSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pacira BioSciences	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
Supernus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Pacira BioSciences has a net margin of 0.70% compared to Supernus Pharmaceuticals' net margin of -3.74%. Supernus Pharmaceuticals' return on equity of 13.07% beat Pacira BioSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pacira BioSciences	0.70%	10.24%	5.47%
Supernus Pharmaceuticals	-3.74%	13.07%	9.66%

99.7% of Pacira BioSciences shares are held by institutional investors. 6.4% of Pacira BioSciences shares are held by company insiders. Comparatively, 8.8% of Supernus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Pacira BioSciences had 3 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 4 mentions for Pacira BioSciences and 1 mentions for Supernus Pharmaceuticals. Supernus Pharmaceuticals' average media sentiment score of 1.89 beat Pacira BioSciences' score of 0.62 indicating that Supernus Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Pacira BioSciences	Positive
Supernus Pharmaceuticals	Very Positive

Pacira BioSciences has a beta of 0.29, meaning that its share price is 71% less volatile than the broader market. Comparatively, Supernus Pharmaceuticals has a beta of 0.55, meaning that its share price is 45% less volatile than the broader market.

Summary

Supernus Pharmaceuticals beats Pacira BioSciences on 9 of the 16 factors compared between the two stocks.

How does Pacira BioSciences compare to Nektar Therapeutics?

Pacira BioSciences (NASDAQ:PCRX) and Nektar Therapeutics (NASDAQ:NKTR) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, media sentiment, dividends, risk, institutional ownership and earnings.

In the previous week, Nektar Therapeutics had 2 more articles in the media than Pacira BioSciences. MarketBeat recorded 6 mentions for Nektar Therapeutics and 4 mentions for Pacira BioSciences. Nektar Therapeutics' average media sentiment score of 0.68 beat Pacira BioSciences' score of 0.62 indicating that Nektar Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pacira BioSciences	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nektar Therapeutics	0 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Pacira BioSciences has a beta of 0.29, meaning that its stock price is 71% less volatile than the broader market. Comparatively, Nektar Therapeutics has a beta of 1.13, meaning that its stock price is 13% more volatile than the broader market.

99.7% of Pacira BioSciences shares are held by institutional investors. Comparatively, 75.9% of Nektar Therapeutics shares are held by institutional investors. 6.4% of Pacira BioSciences shares are held by insiders. Comparatively, 2.5% of Nektar Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Pacira BioSciences presently has a consensus price target of $29.40, indicating a potential upside of 26.67%. Nektar Therapeutics has a consensus price target of $149.63, indicating a potential upside of 166.09%. Given Nektar Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Nektar Therapeutics is more favorable than Pacira BioSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pacira BioSciences	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
Nektar Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

Pacira BioSciences has higher revenue and earnings than Nektar Therapeutics. Nektar Therapeutics is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pacira BioSciences	$726.41M	1.26	$7.03M	$0.12	193.42
Nektar Therapeutics	$55.23M	34.40	-$164.08M	-$8.42	N/A

Pacira BioSciences has a net margin of 0.70% compared to Nektar Therapeutics' net margin of -284.18%. Pacira BioSciences' return on equity of 10.24% beat Nektar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pacira BioSciences	0.70%	10.24%	5.47%
Nektar Therapeutics	-284.18%	-85.40%	-39.99%

Summary

Pacira BioSciences beats Nektar Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Pacira BioSciences compare to Perrigo?

Perrigo (NYSE:PRGO) and Pacira BioSciences (NASDAQ:PCRX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, media sentiment, risk and earnings.

Perrigo currently has a consensus target price of $19.33, suggesting a potential upside of 73.41%. Pacira BioSciences has a consensus target price of $29.40, suggesting a potential upside of 26.67%. Given Perrigo's higher possible upside, equities research analysts clearly believe Perrigo is more favorable than Pacira BioSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Perrigo	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Pacira BioSciences	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

Pacira BioSciences has a net margin of 0.70% compared to Perrigo's net margin of -43.50%. Pacira BioSciences' return on equity of 10.24% beat Perrigo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Perrigo	-43.50%	9.96%	3.90%
Pacira BioSciences	0.70%	10.24%	5.47%

In the previous week, Perrigo had 4 more articles in the media than Pacira BioSciences. MarketBeat recorded 8 mentions for Perrigo and 4 mentions for Pacira BioSciences. Pacira BioSciences' average media sentiment score of 0.62 beat Perrigo's score of -0.47 indicating that Pacira BioSciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Perrigo	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	6 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pacira BioSciences	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

95.9% of Perrigo shares are held by institutional investors. Comparatively, 99.7% of Pacira BioSciences shares are held by institutional investors. 0.4% of Perrigo shares are held by company insiders. Comparatively, 6.4% of Pacira BioSciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Pacira BioSciences has lower revenue, but higher earnings than Perrigo. Perrigo is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Perrigo	$4.25B	0.36	-$1.43B	-$13.10	N/A
Pacira BioSciences	$726.41M	1.26	$7.03M	$0.12	193.42

Perrigo has a beta of 0.51, suggesting that its stock price is 49% less volatile than the broader market. Comparatively, Pacira BioSciences has a beta of 0.29, suggesting that its stock price is 71% less volatile than the broader market.

Summary

Pacira BioSciences beats Perrigo on 12 of the 16 factors compared between the two stocks.

How does Pacira BioSciences compare to Omeros?

Omeros (NASDAQ:OMER) and Pacira BioSciences (NASDAQ:PCRX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, media sentiment, valuation, analyst recommendations and institutional ownership.

Omeros has a beta of 2.52, meaning that its stock price is 152% more volatile than the broader market. Comparatively, Pacira BioSciences has a beta of 0.29, meaning that its stock price is 71% less volatile than the broader market.

48.8% of Omeros shares are held by institutional investors. Comparatively, 99.7% of Pacira BioSciences shares are held by institutional investors. 12.9% of Omeros shares are held by insiders. Comparatively, 6.4% of Pacira BioSciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Pacira BioSciences has higher revenue and earnings than Omeros. Omeros is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omeros	N/A	N/A	-$3.35M	$0.70	14.24
Pacira BioSciences	$726.41M	1.26	$7.03M	$0.12	193.42

Omeros currently has a consensus price target of $40.33, indicating a potential upside of 304.55%. Pacira BioSciences has a consensus price target of $29.40, indicating a potential upside of 26.67%. Given Omeros' stronger consensus rating and higher possible upside, equities research analysts plainly believe Omeros is more favorable than Pacira BioSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omeros	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83
Pacira BioSciences	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

Pacira BioSciences has a net margin of 0.70% compared to Omeros' net margin of 0.00%. Pacira BioSciences' return on equity of 10.24% beat Omeros' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omeros	N/A	-102.16%	64.87%
Pacira BioSciences	0.70%	10.24%	5.47%

In the previous week, Pacira BioSciences had 1 more articles in the media than Omeros. MarketBeat recorded 4 mentions for Pacira BioSciences and 3 mentions for Omeros. Pacira BioSciences' average media sentiment score of 0.62 beat Omeros' score of 0.38 indicating that Pacira BioSciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Omeros	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pacira BioSciences	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Pacira BioSciences beats Omeros on 9 of the 16 factors compared between the two stocks.

How does Pacira BioSciences compare to Assembly Biosciences?

Assembly Biosciences (NASDAQ:ASMB) and Pacira BioSciences (NASDAQ:PCRX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations, institutional ownership and media sentiment.

In the previous week, Assembly Biosciences had 2 more articles in the media than Pacira BioSciences. MarketBeat recorded 6 mentions for Assembly Biosciences and 4 mentions for Pacira BioSciences. Pacira BioSciences' average media sentiment score of 0.62 beat Assembly Biosciences' score of 0.37 indicating that Pacira BioSciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Assembly Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pacira BioSciences	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Pacira BioSciences has a net margin of 0.70% compared to Assembly Biosciences' net margin of -8.98%. Pacira BioSciences' return on equity of 10.24% beat Assembly Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Assembly Biosciences	-8.98%	-4.21%	-3.14%
Pacira BioSciences	0.70%	10.24%	5.47%

Pacira BioSciences has higher revenue and earnings than Assembly Biosciences. Assembly Biosciences is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Assembly Biosciences	$72.30M	4.99	-$6.12M	-$0.11	N/A
Pacira BioSciences	$726.41M	1.26	$7.03M	$0.12	193.42

Assembly Biosciences presently has a consensus target price of $42.75, indicating a potential upside of 88.16%. Pacira BioSciences has a consensus target price of $29.40, indicating a potential upside of 26.67%. Given Assembly Biosciences' stronger consensus rating and higher possible upside, research analysts clearly believe Assembly Biosciences is more favorable than Pacira BioSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Assembly Biosciences	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Pacira BioSciences	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

19.9% of Assembly Biosciences shares are held by institutional investors. Comparatively, 99.7% of Pacira BioSciences shares are held by institutional investors. 5.1% of Assembly Biosciences shares are held by company insiders. Comparatively, 6.4% of Pacira BioSciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Assembly Biosciences has a beta of 1.07, meaning that its stock price is 7% more volatile than the broader market. Comparatively, Pacira BioSciences has a beta of 0.29, meaning that its stock price is 71% less volatile than the broader market.

Summary

Pacira BioSciences beats Assembly Biosciences on 10 of the 16 factors compared between the two stocks.

Get Pacira BioSciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PCRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PCRX vs. The Competition

Export

Metric	Pacira BioSciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$899.49M	$3.30B	$6.64B	$12.06B
Dividend Yield	N/A	2.33%	2.67%	5.55%
P/E Ratio	193.43	10.40	20.93	22.06
Price / Sales	1.26	297.55	508.64	105.22
Price / Cash	5.93	118.24	42.36	56.09
Price / Book	1.44	8.06	10.47	6.72
Net Income	$7.03M	$23.83M	$3.56B	$337.35M
7 Day Performance	4.31%	-2.82%	-1.11%	-2.54%
1 Month Performance	0.26%	2.22%	1.28%	1.42%
1 Year Performance	-8.69%	37.70%	21.20%	24.71%

Pacira BioSciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PCRX Pacira BioSciences	3.6352 of 5 stars	$23.21 +1.5%	$29.40 +26.7%	-12.0%	$899.49M	$726.41M	193.43	720
SUPN Supernus Pharmaceuticals	3.7232 of 5 stars	$44.76 -3.1%	$62.17 +38.9%	+34.2%	$2.68B	$718.95M	N/A	580	Positive News
NKTR Nektar Therapeutics	2.6893 of 5 stars	$63.86 -1.6%	$149.63 +134.3%	+466.8%	$2.19B	$55.23M	N/A	220
PRGO Perrigo	3.5813 of 5 stars	$10.75 -2.8%	$19.33 +79.9%	-55.7%	$1.53B	$4.18B	N/A	8,100	News Coverage Gap Down
OMER Omeros	3.3238 of 5 stars	$10.72 -2.9%	$40.33 +276.2%	+161.3%	$775.86M	$9.89M	15.31	210	Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PCRX) was last updated on 6/9/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pacira BioSciences (PCRX) Competitors

PCRX vs. SUPN, NKTR, PRGO, OMER, and ASMB

How does Pacira BioSciences compare to Supernus Pharmaceuticals?

Summary

How does Pacira BioSciences compare to Nektar Therapeutics?

Summary

How does Pacira BioSciences compare to Perrigo?

Summary

How does Pacira BioSciences compare to Omeros?

Summary

How does Pacira BioSciences compare to Assembly Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PCRX vs. The Competition

Pacira BioSciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pacira BioSciences (PCRX) Competitors

PCRX vs. SUPN, NKTR, PRGO, OMER, and ASMB

How does Pacira BioSciences compare to Supernus Pharmaceuticals?

Which has stronger valuation and earnings, PCRX or SUPN?

Do analysts rate PCRX or SUPN?

Is PCRX or SUPN more profitable?

Do insiders and institutionals believe in PCRX or SUPN?

Does the media refer more to PCRX or SUPN?

Which has more volatility and risk, PCRX or SUPN?

Summary

How does Pacira BioSciences compare to Nektar Therapeutics?

Does the media refer more to PCRX or NKTR?

Which has more volatility & risk, PCRX or NKTR?

Do institutionals & insiders believe in PCRX or NKTR?

Do analysts rate PCRX or NKTR?

Which has better earnings & valuation, PCRX or NKTR?

Is PCRX or NKTR more profitable?

Summary

How does Pacira BioSciences compare to Perrigo?

Do analysts rate PRGO or PCRX?

Is PRGO or PCRX more profitable?

Does the media favor PRGO or PCRX?

Do insiders & institutionals have more ownership in PRGO or PCRX?

Which has higher earnings & valuation, PRGO or PCRX?

Which has more risk & volatility, PRGO or PCRX?

Summary

How does Pacira BioSciences compare to Omeros?

Which has more volatility & risk, OMER or PCRX?

Do insiders and institutionals hold more shares of OMER or PCRX?

Which has preferable valuation & earnings, OMER or PCRX?

Do analysts prefer OMER or PCRX?

Is OMER or PCRX more profitable?

Does the media favor OMER or PCRX?

Summary

How does Pacira BioSciences compare to Assembly Biosciences?

Does the media favor ASMB or PCRX?

Is ASMB or PCRX more profitable?

Which has stronger valuation and earnings, ASMB or PCRX?

Do analysts prefer ASMB or PCRX?

Do insiders & institutionals hold more shares of ASMB or PCRX?

Which has more risk and volatility, ASMB or PCRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PCRX vs. The Competition

Pacira BioSciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools